-+ 0.00%
-+ 0.00%
-+ 0.00%

Viatris To Present Five Abstracts From Phase 3 Program Evaluating Formulation Of Meloxicam In Moderate-To-Severe Acute Surgical Pain Models At PAINWeek 2025 National Conference

Benzinga·08/01/2025 14:06:16
Listen to the news

Presentations to include efficacy, safety and opioid use reduction data in two different surgery models as well as pharmacokinetics data 

PITTSBURGH, Aug. 1, 2025 /PRNewswire/ -- Viatris (NASDAQ:VTRS), a global healthcare company, today announced that five abstracts from its Phase 3 program evaluating novel fast-acting formulation of meloxicam (MR-107A-02) in moderate-to-severe acute surgical pain models will be presented at the PAINWeek 2025 national conference in Las Vegas from September 2-5, 2025.

The presentations will include positive results from two previously announced pivotal studies in herniorrhaphy (NCT06215859) and bunionectomy (NCT06215820) surgery models. All accepted scientific abstracts are now available on the PAINWeek website.